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Abstract
Background: Fibrillary glomerulonephritis is a rare cause of progressive renal dysfunction, often
leading to the need for dialysis within a few years. The role of immunosuppressive treatment is still
uncertain although this has been tried with variable success.
Case presentation: A 56 year old woman with the antiphospholipid antibody syndrome (IgM
anticardiolipin antibodies) was seen in the nephrology clinic with haematuria, proteinuria, and
worsening renal function. A renal biopsy demonstrated a mesangial proliferative glomerulonephritis
on light microscopy and smaller fibrils (10.6–13.8 nm in diameter) than is usual for fibrillary
glomerulonephritis (typically 18–22 nm) on electron microscopy. Amyloidosis was excluded
following detailed evaluation. On account of rapidly worsening renal failure she was started on
cyclophosphamide and prednisolone which led to the partial recovery and stabilization of her renal
function.
Conclusion: This case highlights the need for routine electron microscopy in native renal biopsies,
where the differential diagnosis is wide and varied and the light and immunofluorescence
microscopic findings may be non specific.
Background
Fibrillary glomerulonephritis (FibGN) is a rare cause of
progressive renal dysfunction. The majority of patients
who develop the disease require dialysis within a few
years [1]. It was first described by Rosenmann and Eliakim
in 1977 as an amyloid-like glomerulopathy but with neg-
ative congo red staining [2]. Alpers et al introduced the
term FibGN in 1987 [3]. It is characterized by the deposi-
tion of randomly arranged fibrils in the mesangium and
glomerular basement membrane. The fibrils are generally
less than 30 nm in diameter, with the majority measuring
approximately 20 nm. This condition is closely related to
immunotactoid glomerulopathy (see table 1) [4-8]. There
is some overlap between these two conditions, which has
led some pathologists to propose that they should be clas-
sified together as one entity [9].
Light microscopy typically demonstrates a mesangiopro-
liferative or a membranoproliferative glomerulonephritis.
Glomerular crescents are present in about 25% of biopsies
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[1,10]. Immunofluorescence may demonstrate IgG and
C3, IgG4 being the predominant IgG subtype [5,6]. IgA,
IgM and C1q deposition are less commonly found.
We report a case of FibGN in a 56 year old woman. The
size of her fibrils were rather small ranging between 10.6–
13.8 nm. Further detailed evaluation did not demonstrate
amyloid deposition. On account of rapidly worsening
renal failure she was started on a trial of cyclophospha-
mide and prednisolone which led to the partial recovery
and stabilization of her renal function.
Case Presentation
A 56 year old woman was referred to the nephrology out-
patient clinic, in November 2004 with haematuria, pro-
teinuria, and worsening renal function. Her only
complaints were of intermittent macroscopic haematuria
and right upper quadrant colicky abdominal pain.
Her past medical history included hypertension, hyperlip-
idaemia and psoriasis. Additionally, she had an appendi-
cectomy aged 16 and a cholecystectomy in 1984. She had
been diagnosed with the antiphospholipid antibody syn-
drome (IgM anticardiolipin antibodies) following an epi-
sode of branch retinal artery thrombosis in September
2003, and a transient ischaemic attack in January 2004.
Her medications included warfarin, atorvastatin and
perindopril, although the latter had just been stopped by
her General Practitioner.
At the time of her initial review in the renal out-patient
clinic, her blood pressure was 164/90 mmHg. Her urine
dipstick contained blood (+++) and protein quantified at
0.52 g in 24 hours. Serum albumin levels were low at 31
g/l. An ultrasound scan demonstrated normal kidneys
with a small benign cyst on her left kidney. An IVU and
cystoscopy were reported as normal. Her serum creatinine
levels measured 84 μmol/l in July 2003, 150 μmol/l in
November 2004, and 300 μmol/l in January 2005. Further
investigations showed a haemoglobin level of 8 g/dl.
Serum Folate levels were normal; however, B12 and Ferri-
tin levels were low at 171 pg/ml and 33.7 ng/ml respec-
tively. Gastric parietal cell antibodies and intrinsic factor
antibodies were not detected.
ANA, ENA, ANCA and dsDNA antibodies, rheumatoid
factor and cryoglobylins were not demonstrated. Serum
angiotensin converting enzyme (ACE) levels and comple-
ment (C3 & C4) were within normal limits.
Serology for Hepatitis B and C was negative. C reactive
protein levels were measured at 4 mg/l. Her ESR and
plasma viscosity were elevated at 76 mm/hr and 1.98
mPas respectively. Serum electrophoresis revealed no
abnormalities, and Bence-Jones proteins were not
detected in a urine specimen.
Light microscopy showed nine glomeruli, two of which
were globally sclerosed. Of the remainder, many showed
a mesangial matrix increase with hypercellularity, without
the evidence of necrotizing lesions or fibrin thrombi (fig.
1). Silver stain showed basement membrane wrinkling,
but no evidence of spikes or double contours. In a single
glomerulus on one level, there was prominence of the epi-
thelial cells of Bowman's capsule, possibly with some
associated fibrin possibly representing an early crescent
(fig. 2). Established crescents were not seen. There was a
moderate and patchy interstitial inflammatory infiltrate.
There was no interstitial fibrosis or evidence of tubular
Table 1: Classification and clinical features of fibrillary and immunotactoid glomerulopathies
Fibrillary glomerulonephritis Immunotactoid glomerulopathy
Composition Fibrils Microtubules
Fibril or microtubule size Average diameter 18–22 nm (usual range 12–30 nm) Typically >30 nm (range 16–90 nm)
Arrangement of fibrils or microtubules Randomly arranged fibrils Parallel arrays of microtubules
Immunoglobulin type Usually polyclonal (mostly IgG4 sometimes with IGg1) 
occasionally monoclonal (IgGκ)
Usually monoclonal IgGκ or IgGλ
Light microscopy Mesangial proliferation, membranoproliferative GN 
crescentic GN, sclerosing GN diffuse proliferative GN 
with endocapilliary exudation
Atypical membranous GN, diffuse proliferative GN 
membranoproliferative GN
Association with lymphoproliferative disorder Uncommon Common (chronic lymphocytic leukaemia, nonHodgkin 
lymphoma)
Renal presentation Sub nephrotic or nephrotic range proteinuria + 
haematuria hypertension, rapidly progressive 
glomerulonephritis
Nephrotic syndrome with microhaematuria and 
hypertension
Other manifestations (fibrillar deposits) Pulmonary haemorrhage Microtubular inclusions in leukaemic lymphocytes
Treatment Various immunosuppressive drugs tried with variable 
response (see table 1)
Treatment of the associated lymphoproliferative 
disorder
Racial predilection Predominantly Caucasian Predominantly Caucasian
Peak occurrence 5th to 6th decades Age 60 years
Prognosis Established renal failure in half of patients within 2–4 
years
Probably better renal prognosis than fibrillary GN
Frequency in renal biopsies Approximately 1 % of renal biopsies 0.06% of renal biopsiesBMC Nephrology 2007, 8:7 http://www.biomedcentral.com/1471-2369/8/7
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atrophy. Some tubules contained red cells (fig. 3). The
arteries showed focal thickening of their walls. Immun-
ofluorescence showed diffuse patchy granular mesangial
and peripheral IgG (2+), C3 (+), and IgM (+) (fig 4). IgA
and C1q were negative. The appearance was essentially of
a mesangial proliferative glomerulonephritis. Congo red
stain was negative. Immunohistochemistry for AA, AL and
Aβ2M amyloid were negative.
Electron microscopy of a single glomerulus showed
numerous fibrils with a diameter of 10.6–13.8 nm and
within an expanded mesangial matrix. These findings sug-
gested the diagnosis of FibGN although the small fibre
size was somewhat suggestive of amyloid (FibGN typi-
cally has larger fibers, average diameter 20 nm).
Red cells and red cell cast in tubules (Masson trichrome stain,  original magnification ×100) Figure 4
Red cells and red cell cast in tubules (Masson trichrome stain, 
original magnification ×100).
Kidney biopsy showing possible early crescent (haematoxylin  and eosin stain, original magnification × 100) Figure 2
Kidney biopsy showing possible early crescent (haematoxylin 
and eosin stain, original magnification × 100).
Electron micrograph or kidney biopsy demonstrating fibrils  ranging in size from 10.6 to 13.8 nm (original magnification ×  64000) Figure 1
Electron micrograph or kidney biopsy demonstrating fibrils 
ranging in size from 10.6 to 13.8 nm (original magnification × 
64000).
Kidney biopsy showing mesangial proliferative changes (hae- matoxylin and eosin stain, original magnification ×100) Figure 3
Kidney biopsy showing mesangial proliferative changes (hae-
matoxylin and eosin stain, original magnification ×100).BMC Nephrology 2007, 8:7 http://www.biomedcentral.com/1471-2369/8/7
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She was referred to the National Amyloidosis Centre who
also assessed her renal biopsy and did not find evidence
of amyloid. They assessed her serum free light chains,
demonstrating slightly increased kappa levels at 29.3 mg/
l and lambda levels at 39.7 mg/l, probably the conse-
quence of the decreased renal clearance of normal light
chains in this patient. However, the κ/λ ratio was normal
at 0.74 (range 0.26–1.65). Furthermore, serum amyloid P
(SAP) scintigraphy did not reveal visceral amyloid deposi-
tion. A final diagnosis of FibGN was made.
Once her serum creatinine levels reached 300 μmol/l in
January 2005, she was started on Prednisolone (40 mg
daily) and cyclophosphamide (100 mg daily). In addition
she received intravenous iron therapy, B12 injections and
erythropoietin beta. Her blood pressure was treated with
perindopril and amlodipine.
Following the initiation of immunosuppressive treat-
ment, her serum creatinine levels improved to178 μmol/l
in four weeks. Cyclophosphamide treatment was briefly
withheld on two occasions in March and in May 2005 due
to various minor infections, during which time her serum
creatinine increased to 280 and 270 μmol/l respectively.
Creatinine levels again improved on restarting immuno-
suppressive treatment to levels of approximately 200
μmol/l. Her renal function remained stable subsequently.
Over the next year of follow, the dose of her cyclophos-
phamide was maintained while her prednisolone was
slowly reduced to 5 mg daily. Following discontinuation
of immunosuppressive treatment after a year, serum creat-
inine levels remained stable over the next 6 months of fol-
low up (fig. 5).
During the course of her illness, she had an episode of
haematemisis and fresh bleeding per rectum. She also
complained of easy skin bruising and had an episode of
macroscopic haematuria. Upper gastrointestinal endos-
copy and colonoscopy were normal. Unfortunately, a
request, with the patient's permission to obtain biopsies
at endoscopy to look for fibrils was inadvertently not car-
ried out. A chest X-ray carried out to investigate a cough
was reported as showing a bulky left hilum but a com-
puted tomography scan of chest and upper abdomen was
normal.
FibGN occurs in approximately 1% of renal biopsies
[[8,11] and [12]]. It is more common in Caucasians with
a peak incidence between the fifth and the sixth decades
of life [11].
Since the patient had been diagnosed with the antiphos-
pholipid antibody syndrome, the presence of mesangio-
proliferative glomerulonephritis on light microscopy,
initially suggested the diagnosis of lupus nephritis. How-
ever the presence of fibrils in the mesangium on electron
microscopy and the negative staining for amyloid pointed
to a diagnosis of FibGN, a condition with a relatively poor
prognosis. It is quite possible that the diagnosis may be
underreported where light microscopic findings are not
routinely complemented by electron microscopy.
The fibrils in our patient were 10.6–13.8 nm in diameter.
Fibrils of this size are possible in amyloidosis, which is
characterized by the deposition of proteinaceous material
in extracellular spaces, composed of a felt like array of
7.5–10 nm wide, linear, non branching fibrils of indefi-
nite length [13]. In our patient, congo red staining, immu-
nohistochemistry and SAP scintigraphy did not reveal
amyloid.
Symptoms in FibGN are usually nonspecific and consist
of proteinuria, haematuria, hypertension and renal insuf-
ficiency. Fibril deposition is predominantly confined to
the kidneys. However, fibrillary deposits have been
reported in the alveolar capillary membrane, producing a
pulmonary-renal syndrome, and in the skin of a patient
with leukocytoclastic skin vasculitis [7,12,14]. Whether
the episodes skin bruising, haematemesis, and rectal
bleeding in our patient was due to fibrillary deposition in
these organs or not is not known. Our patient was under-
standably not keen to be subjected to further biopsies to
confirm the deposition of fibrils elsewhere.
The pathogenesis of FibGN is not clearly understood at
present. Immunofluorescence findings suggest an immu-
nogenic origin. There in no definitive treatment for this
condition. A few cases have been reported in the literature
where immunosuppressive treatment has been used with
varying success (see table 2) [15-32]. Half of all cases
develop end stage renal failure within 4 years of diagnosis
[31]. Although recurrence after renal transplantation has
been described, the progression of renal dysfunction is
often slow [31]. In our patient prednisolone and oral
cyclophosphamide was started due to moderately rapidly
Changes in estimated GFR (abbreviated MDRD formula)  with time (see text for details) Figure 5
Changes in estimated GFR (abbreviated MDRD formula) 
with time (see text for details).BMC Nephrology 2007, 8:7 http://www.biomedcentral.com/1471-2369/8/7
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deteriorating renal function. Renal function improved
substantially within four weeks of initiating treatment and
remained stable to date after more than a year of follow
up. It is interesting to note that early in the course of her
illness, treatment was briefly stopped on two occasions
during which her serum creatinine levels increased.
Conclusion
This case highlights the need for routine electron micros-
copy in native renal biopsies, where the differential diag-
nosis is wide and varied and the light and
immunofluorescence microscopic findings may be non
specific.
The diagnosis of FibGN cannot be made on the basis of
the size of the fibrils alone. A therapeutic trial of cyclo-
phosphamide and prednisolone in patients with progres-
sive renal dysfunction who are able to tolerate the
treatment, and who understand the risks is worthwhile.
This may prevent or slow down the progression of renal
failure.
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